Verve Therapeutics

About Us
Why Cardiovascular Disease
Our Approach

Our Pipeline
Culture & Careers
Investors

Looking to leapfrog antibodies and RNAi, Sekar Kathiresan says gene editing approach to cut PCSK9 looks durable

Post navigation

Previous PostPrevious The biotech Verve is gearing up to test a gene-editing treatment that could cure heart disease. The CEO shares his 3-step vision for the one-and-done heart treatment.

Next PostNext With durable monkey data, Verve selects its first CRISPR base editing treatment for human trials

Verve Therapeutics, Inc., all rights reserved

Contact Us
Privacy Policy

Home
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
►
Contact Us